Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN C R versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN C R versus LAROTID.
BICILLIN C-R vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzathine penicillin G and procaine penicillin G are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes, leading to cell lysis.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
1.2 million units intramuscularly as a single dose (600,000 units procaine penicillin G and 600,000 units benzathine penicillin G) for moderate to severe infections; for mild infections, 600,000 units intramuscularly as a single dose.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
Penicillin G: 0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria. Benzathine component sustains low levels for days; effective half-life of benzathine penicillin G is 3-5 days due to slow release.
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Renal excretion primarily via glomerular filtration and tubular secretion; approximately 60-70% of penicillin G is excreted unchanged in urine within 6 hours; benzathine and procaine components are metabolized and excreted renally as well; small amounts in bile and feces.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic